INS and hepatocellular carcinoma: According to network meta-analysis, metformin was significantly effective in reducing the risk of HCC when compared with sulphonylurea (RR 0.45, 95% CI 0.27–0.74) and insulin (RR 0.28, 95% CI 0.17–0.47).